Neuromuscular Blocking Drugs in Pediatric Patients

Brandom, Barbara W.

doi:10.1097/00000539-200005001-00004

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Higher costs are a major disincentive for the pharmaceutical industry to fund trials in children, particularly when the market size is small and return on investment is limited. Methodological issues which relate specifically to research in children include fragmented information from smaller and more heterogeneous populations …”

Section: Discussionmentioning

confidence: 99%

Neuromuscular‐blocking agents for tracheal intubation in pediatric patients (0‐12 years): A systematic review and meta‐analysis

Vanlinthout

Geniets

Driessen

et al. 2020

Pediatric Anesthesia

View full text Add to dashboard Cite

Background:The benefit of using neuromuscular-blocking agents to facilitate tracheal intubation in pediatric patients remains unclear due to variations in design, treatments, and results among trials. By combining the available evidence, we aimed to establish whether scientific findings are consistent and can be generalized across various populations, settings, and treatments. Methods:A systematic search for randomized controlled trials, related to the use of neuromuscular-blocking agents for tracheal intubation in American Society of Anesthesiologists class I-II participants (0-12 years), was performed. We considered all randomized controlled trials that studied whether intubation conditions and hemodynamics obtained by using neuromuscular-blocking agents were equivalent to those that were achieved without neuromuscular-blocking agents. We combined the outcomes in Review Manager 5.3 (RevMan, The Cochrane Collaboration) by pairwise random-effects meta-analysis using a risk ratio (RR) for intubation conditions and mean difference for hemodynamic values (mean [95% Confidence Intervals]).Heterogeneity among trials was explored using sensitivity analyses. Results:We identified 22 eligible randomized controlled trials with 1651 participants.Overall, the use of a neuromuscular-blocking agent was associated with a clinically important increase in the likelihood of both excellent (RR = 1.41 [1.19-1.68], I 2 = 76%) and acceptable (RR = 1.13 [1.07-1.19], I 2 = 68%) intubating conditions. There is strong evidence that both unacceptable intubation conditions (RR = 0.35 [0.22-0.46], I 2 = 23%) and failed first intubation attempts (RR = 0.25 [0.14-0.42], I 2 = 0%) were less likely to occur when a neuromuscular-blocking agent was used compared with when it was not. Higher systolic or mean arterial pressures (mean difference = 13.3 [9.1-17.5] mm Hg, I 2 = 69%) and heart rates (mean difference = 15.9 [11.0-20.8] beats/ min, I 2 = 75%) as well as a lower incidence of arrhythmias were observed when tracheal intubation was facilitated by neuromuscular-blocking agents. Conclusion:The use of a neuromuscular-blocking agent during light-to-moderate depth of anesthesia can improve the quality as well as the success rate of tracheal intubation and is associated with better hemodynamic stability during induction of anesthesia. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Vanlinthout LE, Geniets B, Driessen JJ, et al. Neuromuscular-blocking agents for tracheal intubation in pediatric patients: A systematic review and meta-analysis.

show abstract

Section: Discussionmentioning

confidence: 99%